Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both

New England Journal of Medicine

Volumn 352, Issue 25, 2005, Pages 2581-2588

  Solomon, Scott D ^a   Zelenkofske, Steve ^b   McMurray, John J V ^c   Finn, Peter V ^a   Velazquez, Eric ^d   Ertl, George ^e   Harsanyi, Adam ^f   Rouleau, Jean L ^g   Maggioni, Aldo ^h   Kober, Lars ⁱ   White, Harvey ^j   Van De Werf, Frans ^k   Pieper, Karen ^d   Califf, Robert M ^d   Pfeffer, Marc A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c WESTERN INFIRMARY   (United Kingdom)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f National Center for Health Services   (Hungary)

^g MONTREAL HEART INSTITUTE   (Canada)

^h ANMCO RESEARCH CENTER   (Italy)

ⁱ Rigshospitalet   (Denmark)

^j GREEN LANE HOSPITAL   (New Zealand)

^k Leuven Coordinating Center   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RESUSCITATION; SUDDEN DEATH; TIME; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; RANDOMIZED CONTROLLED TRIAL; RISK;

AGED; DEATH, SUDDEN, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HEART ARREST; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RESUSCITATION; RISK; STROKE VOLUME; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 20544436649     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa043938     Document Type: Article

References (21)

1. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82.
2. Savard P, Rouleau JL, Ferguson J, et al. Risk stratification after myocardial infarction using signal-averaged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location. Circulation 1997;96:202-13.
3. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998;98:2334-51.
4. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309:331-6.
5. Mukharji RJ, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: two year follow-up. Am J Cardiol 1984;54:31-6.
6. Al-Khatib SM, Sanders GD, Mark DB, et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J (in press).
7. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-90. [Erratum, N Engl J Med 2000;342:1300.]
8. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
9. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:e82-e292.
10. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-8.
11. Huikuri HV, Tapanainen JM, Lindgren K, et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2003;42:652-8.
12. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906. [Erratum, N Engl J Med 2004;350:203.]
13. Califf RM, McKinnis RA, Burks J, et al. Prognostic implications of ventricular arrhythmias during 24 hour ambulatory monitoring in patients undergoing cardiac catheterization for coronary artery disease. Am J Cardiol 1982;50:23-31.
14. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, tran-sient risk, and intervention assessment. Ann Intern Med 1993;119:1187-97.
15. Naccarella F, Lepera G, Rolli A. Arrhythmic risk stratification of post-myocardial infarction patients. Curr Opin Cardiol 2000;15:1-6.
16. Steinberg JS, Regan A, Sciacca RR, Bigger JT Jr, Fleiss JL. Predicting arrhythmic events after acute myocardial infarction using the signal-averaged electrocardiogram. Am J Cardiol 1992;69:13-21.
17. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62.
18. Every N, Hallstrom A, McDonald KM, et al. Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease. Am Heart J 2002;144:390-6.
19. Hohnloser SH, Connolly SJ, Kuck KH, et al. The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): study protocol. Am Heart J 2000;140:735-9.
20. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. Circulation 2000;102:611-6.
21. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.